Abbott Laboratories: Navigating Growth Amidst Diagnostic Headwinds and Share Buyback Commitment

Abbott Laboratories reported Q3 revenue up 6.9% YoY but missed Wall Street expectations. The company reaffirmed its full-year outlook and completed a share repurchase program, contributing to a positive shift in analyst sentiment. Despite revenue shortfall, Abbott's ability to maintain its outlook and return capital to shareholders through buybacks is a positive factor for investors.